ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Reticuline modulates astrocyte and microglial responses to enhance prognosis after traumatic brain injury.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design, synthesis, and anti-inflammatory evaluation of novel analogues derived from the natural product reticuline.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) poses a serious threat to public health due to its high disability and mortality rates. Therefore, it is crucial to explore effective therapeutic strategies. Studies have shown that reticuline may exert a cardioprotective effect by blocking the JAK-STAT signaling pathway, but its effect in TBI has not been explored. Therefore, this study aimed to evaluate the potential clinical value of reticuline after TBI and its impact on the inflammatory quiescent state. This study assessed the therapeutic effect of reticuline administered intraperitoneally using the controlled cortical impact (CCI) model in adult rats. In addition, to clarify the mechanism of action of reticuline, we used Colivelin, a STAT3 agonist, to restore the function of related signal pathways and explore its intervention effect. The study showed that reticuline inhibited neuroinflammation and promoted neurological function recovery after TBI by regulating the JAK-STAT signaling pathway, reducing the toxic response of astrocytes and microglia while retaining its neuroprotective effect. In summary, this study reveals that reticuline may promote neural repair after TBI through a JAK-STAT-dependent anti-inflammatory effect. Our findings further expand its potential application value in brain injury treatment and provide new ideas for intervention strategies for TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.